| Code | CSB-RA005490MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to lixudebart, targeting claudin-1 (CLDN1), a tight junction protein critical for maintaining epithelial and endothelial barrier integrity. CLDN1 is a member of the claudin family that regulates paracellular permeability and cell polarity in various tissues. This protein plays a significant role in pathological conditions, serving as an essential entry co-receptor for hepatitis C virus and being aberrantly expressed in multiple cancers including colorectal, gastric, and hepatocellular carcinomas, where it contributes to tumor progression and metastasis.
Lixudebart represents an investigational therapeutic antibody designed to target CLDN1-expressing malignancies, particularly in gastrointestinal cancers. As a research-grade biosimilar, this antibody provides investigators with a valuable tool for studying CLDN1-mediated signaling pathways, tight junction dynamics, viral entry mechanisms, and tumor microenvironment interactions. It supports exploratory studies in oncology, virology, and epithelial biology research, enabling scientists to investigate potential therapeutic strategies targeting CLDN1 in disease contexts.
There are currently no reviews for this product.